Major depressive disorder (MDD) is one of the most prevalent major psychiatric disorders with a lifetime prevalence of 17%. Recent evidence suggests MDD is not only a brain dysfunction, but a systemic disease affecting the whole body. Central and peripheral inflammatory changes seem to be a centerpiece of MDD pathology: a subset of patients show elevated blood cytokine and chemokine levels that partially normalize with symptom improvement over the course of anti-depressant treatment. As this inflammatory process in MDD is poorly understood, we hypothesized that the peripheral tissues of MDD patients will respond differently to inflammatory stimuli, resulting in an aberrant transcriptional response to elevated pro-inflammatory cytokines. To test this, we used MDD patient-and control-derived dermal fibroblast cultures to investigate their response to an acute treatment with IL6, IL1β, TNFα, or vehicle. Following RNA isolation and subsequent cDNA synthesis, quantitative PCR was used to determine the relative expression level of several families of inflammation-responsive genes. Our results showed comparable expression of the tested genes between MDD patients and controls at baseline. In contrast, MDD patient fibroblasts had a diminished transcriptional response to IL6 in all the gene sets tested (oxidative stress response, mitochondrial function, and lipid metabolism). We also found a significant increase in baseline and IL6 stimulated transcript levels of the IL6 receptor gene. This IL6 receptor transcript increase in MDD fibroblasts was accompanied by an IL6 stimulated increase in induction of SOCS3, which dampens IL6 receptor signaling. Altogether our results demonstrate that there is an altered transcriptional response to IL6 in MDD, which may represent one of the molecular mechanisms contributing to disease pathophysiology. Ultimately we hope that these studies will lead to validation of novel MDD drug targets focused on normalizing the altered IL6 response in patients.
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Introduction
Major depressive disorder (MDD) is a major public health concern with a lifetime prevalence of 17% in the United States and a leading cause of disability worldwide (Kessler et al., 2005; Moussavi et al., 2007) . Up to 65% of those who suffer from a major depressive episode will have recurrent episodes (Eaton et al., 2008; Yiend et al., 2009) , and only about a third of adults with MDD are successfully treated with initial therapies (Alexopoulos, 2005; Roose and Schatzberg, 2005) . A potential reason for therapeutic failure is that dysfunction in MDD is not restricted to the brain. MDD is a systemic illness with central and peripheral inflammatory changes at the core of MDD pathology (Erdem et al., 2011; Lisi et al., 2013; Noto et al., 2014; Powell et al., 2014; Setiawan et al., 2015; Shimizu et al., 1996; Slavich and Irwin, 2014) . Patients with inflammatory diseases have a higher incidence of MDD than the general population (Dickens et al., 2002; Graff et al., 2009; Krishnadas et al., 2011; Lo Fermo et al., 2010) , and 20-82% of patients treated with pro-inflammatory cytokines like interferon develop MDD (Capuron et al., 2002; Krishnadas et al., 2011; Musselman et al., 2001; Reichenberg et al., 2005) . Additionally, TNFα antagonists used to decrease systemic inflammation in psoriasis also attenuate depressive symptoms, suggesting a potential causative role for inflammation in the development of MDD (Krishnan et al., 2007; Tyring et al., 2006) . Altered levels of inflammation and immune response have been reported in numerous MDD studies. MDD patients have increased blood levels of acute phase proteins and pro-inflammatory cytokines/ chemokines such as IL6, IL1β, and TNFα (Dahl et al., 2014; Dowlati Neurobiology of Disease 89 (2016) [46] [47] [48] [49] [50] [51] [52] [53] [54] 
